
Evidence analysis
European Antibiotic Awareness Day (EAAD): Media toolkit
What is established Antimicrobial resistance (AMR) is a growing public health concern in Europe and worldwide. It occurs when bacteria and other microorganisms develop mechanisms to withstand the effects of antibiotics, making infections harder to treat and increasing…
Read →
Evidence analysis
Stockholm welcomes scientific experts to ESCAIDE – Europe’s leading annual public health conference
Stockholm Hosts 20th ESCAIDE Conference on Infectious Disease Epidemiology What is established In November 2026, Stockholm hosted the 20th European Scientific Conference on Applied Infectious Disease Epidemiology (ESCAIDE). Organized by the European Centre for Disease Prevention and Control…
Read →
Evidence analysis
Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling study
Economic Value of Gonorrhea Resistance Testing in the United States: An Evidence Review Source: Nichols BE, Wonderly Trainor B, Hampson G, Grad YH, Klausner JD. Economic value of gonorrhea resistance testing in the United States: A multi-perspective modeling…
Read →
Evidence analysis
Schools that ban cellphones see uptick in test scores
What is established A large national study by researchers at Harvard Graduate School of Education’s Center for Education Policy Research (CEPR) has found that schools implementing bans on smartphone use during school hours experience a modest, measurable improvement…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Keytruda, pembrolizumab, Date of authorisation: 17/07/2015, Revision: 73, Status: Authorised
What is established Keytruda (active substance pembrolizumab) is an immunotherapy medicine authorized for use in the European Union since July 2015. It is primarily used to treat various advanced or metastatic cancers, including melanoma (skin cancer), non-small cell…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Talmanco (previously Tadalafil Generics), tadalafil, Date of authorisation: 09/01/2017, Revision: 12, Status: Authorised
What is established Talmanco is a pharmaceutical medication authorized for use in the European Union for the treatment of adults with pulmonary arterial hypertension (PAH). PAH is characterized by abnormally high blood pressure in the arteries of the…
Read →
Evidence analysis
EU recommendations for 2026/2027 seasonal flu vaccine composition
EU Recommendations for 2026/2027 Seasonal Influenza Vaccine Composition: Evidence Dossier What is established Seasonal influenza vaccines are reformulated annually to match circulating virus strains, following surveillance data. For the 2026/2027 season, the European Medicines Agency (EMA) has published…
Read →
Evidence analysis
Towards improving the safety of medication use in pregnancy
Towards Improving the Safety of Medication Use in Pregnancy: Evidence Dossier What is established Pregnant individuals have traditionally been excluded from clinical trials, leaving a significant gap in knowledge regarding the safety and risks of medication use during…
Read →
Evidence analysis
A growing public health worry: Prolonged sitting
What is established Scientific consensus increasingly recognizes prolonged sedentary behavior—especially sitting for more than 6 to 8 hours daily—as a risk factor for adverse health outcomes. Multiple studies have linked extended sitting with negative effects on cardiovascular health,…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Date of authorisation: 24/11/2025, Revision: 1, Status: Authorised
What is established Kyinsu is a newly authorized medication in the European Union for treating type 2 diabetes in adults whose condition is inadequately controlled with basal insulin or GLP-1 receptor agonists. It contains two active components: insulin…
Read →